Hayakawa, T.; Kato, K.-I.; Kobuchi, S.; Kataoka, K.; Sakaeda, T.
Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals 2022, 15, 203.
https://doi.org/10.3390/ph15020203
AMA Style
Hayakawa T, Kato K-I, Kobuchi S, Kataoka K, Sakaeda T.
Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals. 2022; 15(2):203.
https://doi.org/10.3390/ph15020203
Chicago/Turabian Style
Hayakawa, Tetsuo, Ken-Ichiro Kato, Shinji Kobuchi, Kaede Kataoka, and Toshiyuki Sakaeda.
2022. "Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus" Pharmaceuticals 15, no. 2: 203.
https://doi.org/10.3390/ph15020203
APA Style
Hayakawa, T., Kato, K.-I., Kobuchi, S., Kataoka, K., & Sakaeda, T.
(2022). Associations of Plasma Concentration Profiles of Dapagliflozin, a Selective Inhibitor of Sodium–Glucose Co-Transporter Type 2, with Its Effects in Japanese Patients with Type 2 Diabetes Mellitus. Pharmaceuticals, 15(2), 203.
https://doi.org/10.3390/ph15020203